MYC and diffuse large B-cell lymphoma: DLBCL patients with DDX3X mutation have an inferior 5-year overall survival of 22% compared to 72% for patients with no mutated DDX3X allele; although these statistics were assessed independently of the MYC status and inclusion of tumors with MYC translocation in the group of DDX3X mutated tumors could have altered the survival (143).